Wyeth’s Pristiq Shows Reduction In Hot Flashes In Menopausal Women
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm releases data from three studies evaluating the SNRI for the treatment of vasomotor symptoms associated with menopause.
You may also be interested in...
FDA Asks Wyeth For Additional Safety Study To Support Pristiq Vasomotor Claim
Agency’s request will delay potential vasomotor symptoms launch by at least a year, but does not affect FDA review of the Effexor follow-on for major depressive disorder, Chief Medical Officer Stiles says.
FDA Asks Wyeth For Additional Safety Study To Support Pristiq Vasomotor Claim
Agency’s request will delay potential vasomotor symptoms launch by at least a year, but does not affect FDA review of the Effexor follow-on for major depressive disorder, Chief Medical Officer Stiles says.
Depomed’s Gabapentin GR Fails Phase III Postherpetic Neuralgia Study
Outcome is not expected to affect product’s ongoing clinical development for menopausal hot flashes.